Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

VPHM-HALO Report Encouraging Data

ViroPharma Inc. along with partner Halozyme Therapeutics (HALO - Free Report) recently reported positive data from a mid-stage study on the subcutaneous formulation of Cinryze, which is being evaluated in combination with Halozyme's Enhanze technology, for the treatment of patients suffering from hereditary angioedema (HAE). The companies presented the data at the annual meeting of the American Academy of Allergy Asthma & Immunology.

The Enhanze technology is a proprietary drug-delivery platform, using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20). This proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin.

The study demonstrated that the subcutaneous formulation of Cinryze was easy to administer, well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations among patients with HAE. Following the positive data, the companies plan to further evaluate this combination, administered subcutaneously as a single injection in HAE patients.

We note that Cinryze, in the intravenous form, is currently marketed worldwide as a treatment for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.

We are encouraged by the study results and believe that the approval of the subcutaneous formulation of Cinryze will add to the drug’s sales, which increased 42% to $251.2 million in 2011. Higher sales from the drug led to overall growth in ViroPharma’s revenues. For 2012, ViroPharma expects US Cinryze sales to range from $310 to $330 million.

Our View

We currently have a Neutral recommendation on ViroPharma. The stock carries a Zacks #3 Rank (Hold rating) in the short-run. We are pleased with Cinryze’s uptake in the US and expect investors to keep a close watch on the performance of the drug in the European Union, where it was approved in June last year.

Resources

Client Support

Follow Us

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Copyright 2017 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +25% per year. These returns cover a period from 1988-2016 and were examined and attested by Baker Tilly Virchow Krause, LLP, an independent accounting firm. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zack Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Visit performance for information about the performance numbers displayed above.